Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6132409

CCOC(=O)c1ccc(-c2cn3nc(-c4ccc(N5CCC(OCCCCCOC)CC5)cc4)sc3n2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.41
TP53 P04637 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.37
SIRT2 Q8IXJ6 3/20 0.36
DPP4 P27487 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
F10 P00742 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
THRB P10828 1/20 0.35
SIRT1 Q96EB6 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6134395 0.91 MAPT (0.42) MAPTTP53LMNAGAASIRT2
Trifluoroacetic Acid SCHEMBL6132444 0.90 MAPT (0.40) MAPTTP53LMNAGAASIRT2
Trifluoroacetic Acid SCHEMBL6134998 0.89 SIRT2 (0.40) MAPTTP53LMNASIRT2CA12
SCHEMBL6135143 0.88 MAPT (0.42) MAPTTP53LMNAGAASIRT2
SCHEMBL6132169 0.88 MAPT (0.43) MAPTTP53LMNAGAACA12
SCHEMBL6134595 0.87 CA12 (0.42) MAPTTP53GAASIRT2CA12
Trifluoroacetic Acid SCHEMBL6132999 0.86 SIRT2 (0.40) MAPTTP53LMNAGAASIRT2
SCHEMBL6135226 0.86 MAPT (0.43) MAPTTP53GAASIRT2CA12
SCHEMBL6134866 0.85 MAPT (0.44) MAPTTP53LMNAGAACA12
Trifluoroacetic Acid SCHEMBL7325659 0.84 SIRT2 (0.46) MAPTTP53LMNAGAASIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884868-B1 Cyclic hexapeptides having antibiotic activity FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-04-26 US disclosed
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1173472-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-23 EP disclosed
WO-2000064927-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 MAPT 3424/4885TP53 4438/4885LMNA 2471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.